Anxiety disorders, ranging from social phobia to post-traumatic stress disorder, are the most common psychiatric diseases in the United States. Research in mice suggests a link between the gene that encodes Glyoxylase 1 (GLO1) and increased anxiety; however, the mechanism underlying this association has remained unclear. The normal role of GLO1 is to degrade cytotoxic byproducts of glycolysis, a function which has no obvious connection to anxiety. Margaret Distler and colleagues at the University of Chicago asked whether the primary substrate of GLO1, methylglyoxal, might have undocumented neurological effects. Using a mouse model, they demonstrated that methylglyoxal stimulates robust activity from GABAA receptors, which are neuron receptors that respond to neurotransmitters. As pharmaceuticals targeting GABAA receptors are mainstays of anxiety treatment, this study provides a definitive functional link between GLO1 activity and anxiety. The team also showed that the inhibition of GLO1 in mice reduced anxious behavior, suggesting GLO1 as a potential novel therapeutic target in humans. These findings have important clinical implications not only for anxiety disorders, but also for other central nervous system diseases having proposed associations with the gene encoding GLO1, including autism, affective disorders, and schizophrenia.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor